Targeting GRPR is of particular interest, as Morgat et al. observed discordant binding of FDG and GRPR on breast cancer samples, where binding of [68Ga]Ga-RM2, a GRPR antagonist, was significantly higher in samples with low FDG binding [16]. This evidence concerns the gene GRPR and breast cancer.